MedSina
Health library › Evidence-based

Sickle Cell Disease: Navigating Complications and Management

October 11, 2026·5 min read ·MedSina Evidence · PubMed

Sickle cell disease is an inherited blood disorder with wide-ranging complications, requiring comprehensive management strategies to improve patient outcomes and quality of life.

Sickle Cell Disease: Navigating Complications and Management

Sickle cell disease (SCD) is an inherited blood disorder caused by a single gene mutation, affecting millions of people worldwide [2, 5]. It is a multisystemic condition, meaning it can impact many parts of the body, leading to premature deaths and severe chronic complications that significantly affect quality of life, career progression, and financial stability [2, 5]. While simple and effective interventions exist to reduce mortality and morbidity associated with SCD, consistent implementation and equitable access to care remain significant challenges in many regions globally [4, 5].

Neurological Complications and Stroke Prevention

Neurological issues are a significant concern, particularly in children with SCD, and can lead to substantial health problems and even mortality [1, 3]. These complications can be acute or chronic [1]. Common neurological symptoms include headaches, which can be severe, and first-time seizures [1]. Children with SCD may also experience cognitive concerns, which can manifest as poor school performance, and gait abnormalities [1]. These symptoms warrant thorough assessment by clinicians [1].

More severe events include stroke and transient ischemic attacks (TIAs), often referred to as "mini-strokes" [1]. These can be debilitating over a patient's lifespan [3]. A particularly insidious complication is the "silent cerebral infarct" (SCI), which are small areas of brain damage that may not cause immediate, obvious symptoms but can lead to cognitive concerns and poor school performance in children [1, 3]. Recognizing risk factors for central nervous system (CNS) disease and overt disease is crucial for primary care providers, including physicians, physician assistants, and nurse practitioners [3].

Monitoring and Managing Stroke Risk

Children with sickle cell anemia (SCA), a severe form of SCD, face a high risk of stroke due to the nature of the inherited hemoglobinopathy [4]. Effective strategies exist for both primary stroke prevention (preventing a first stroke) and secondary prevention (preventing recurrent strokes) [3, 4].

A key diagnostic tool for assessing stroke risk in children is transcranial Doppler (TCD) ultrasonography [3]. This non-invasive test measures blood flow velocity in the brain's major arteries [3]. Abnormally high blood flow velocities indicate an increased risk of ischemic stroke [3]. Regular TCD screenings, performed at appropriate intervals, are important for identifying children who may benefit from preventative measures [3].

For children identified with an abnormal TCD or those who have experienced an overt stroke, chronic blood transfusion therapy is the primary recommended treatment [4, 6]. The goal of this therapy is to dilute the sickle hemoglobin and maintain the percentage of sickle hemoglobin (Hb S) below 30% to reduce stroke risk [6]. In some specific cases, chronic hypersplenism (an overactive spleen) can make it difficult to maintain the target Hb S levels despite regular transfusions [6]. For these select high-risk children, a splenectomy (surgical removal of the spleen) has been explored as a therapeutic option to optimize transfusion therapy for stroke prevention [6]. Studies have shown that splenectomy can lead to a significant reduction in Hb S percentage in such cases [6].

Despite the proven efficacy of primary stroke prevention strategies, their consistent implementation into clinical practice, particularly in underserved minority populations, is not always achieved in the United States, leaving many children at high risk [4]. When an acute symptomatic stroke occurs, immediate neurology involvement and emergent blood transfusion are critical to limit brain damage and improve outcomes [4]. Chronic transfusion therapy is also a proven secondary preventative modality for those with prior symptomatic stroke [4].

Distinguishing SCD from Autoimmune Conditions

The multisystemic nature of SCD can sometimes make diagnosis challenging, as its clinical features can overlap with those of autoimmune diseases (ADs) [2]. For instance, SCD can affect joints and musculature in ways that resemble conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) [2]. This overlap can make it difficult for clinical hematologists and physicians to differentiate between SCD complications and an emerging autoimmune disease, potentially leading to delayed diagnosis and inappropriate treatment [2]. Accurate knowledge of both SCD and AD clinical findings and laboratory results is essential for physicians to correctly interpret symptoms and avoid diagnostic delays [2].

The Broader Impact of Sickle Cell Disease

Beyond the specific medical complications, living with SCD profoundly impacts individuals globally [5]. People with SCD often experience a reduced quality of life, challenges in career progression, and financial strain [5]. They may also face stigmatization and structural racism, which can contribute to stress and poor mental health outcomes [5]. There are significant global inequalities in SCD care, with the disease being most prevalent in sub-Saharan Africa, India, and the Caribbean, while much of the research, clinical trials, and funding are concentrated in North America, Europe, and the Middle East [5]. Despite these disparities, simple and effective interventions are available to improve outcomes [5].

Sources

Sickle Cell DiseaseSCD ComplicationsStroke PreventionNeurological SymptomsChronic Transfusion Therapy

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.